At a glance
Drug class
Dual GIP and GLP-1 receptor agonist
How it's taken
Once-weekly subcutaneous injection, titrated gradually
Dispensed by
Licensed US pharmacy partner
Indication
FDA-approved to improve glycemic control in adults with type 2 diabetes, alongside diet and exercise.
- FDA-approved for type 2 diabetes
- Dual GIP and GLP-1 mechanism
- Once-weekly dosing
- Dispensed by a licensed US pharmacy
Important safety information
This is a summary, not the full prescribing information. Review the complete label with your provider before starting treatment.
- Boxed warning: thyroid C-cell tumors observed in rodents. Contraindicated with a personal or family history of MTC or MEN2.
- Not indicated for type 1 diabetes.
- Most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation.
How care works
Check eligibility
A fast, mobile-friendly quiz screens for clinical fit and state licensing.
Choose your plan
Transparent monthly pricing. No hidden fees. Cancel or pause anytime.
Clinical intake
Share your history securely. A licensed US provider reviews asynchronously.
Ongoing care
Medication when appropriate, refills, messaging, and progress tracking.
Mounjaro is a registered trademark of Eli Lilly. NexGen Telehealth is not affiliated with, endorsed by, or sponsored by Eli Lilly. This page is informational and is not medical advice. Mounjaro is available by prescription only. A licensed US provider determines whether treatment is appropriate after reviewing your medical history; a prescription is never guaranteed. Pricing shown does not constitute an offer and may vary by pharmacy and dose.